The Q-Line Biotec IPO has started on a strong note, recording an overall subscription of 4.15× on Day 1. The issue has attracted solid interest across all investor categories, especially from institutional and high-net-worth investors, indicating strong market confidence.

As per the latest IPO subscription data, the QIB (Qualified Institutional Buyers) segment subscribed 4.15×, showing steady institutional participation right from the first day. The NII (Non-Institutional Investors) category led the demand with 5.25× subscription, highlighting aggressive participation from high-net-worth investors.

Retail investors also showed healthy interest, with the individual investor category subscribing 3.68×, which reflects decent early retail demand despite being just Day 1 of the issue.

Overall, the IPO received bids for over 1.72 crore shares against 41.58 lakh shares offered, signaling strong early momentum. A total of 11,470 applications were recorded on the first day itself.

📊 Key Highlights

• Total subscription: 4.15×

• QIB subscription: 4.15×

• NII subscription: 5.25×

• Retail subscription: 3.68×

• Total applications: 11,470

📈 Market Outlook

The strong opening subscription, especially in QIB and NII segments, suggests that institutional investors are confident about the company’s prospects. If this trend continues over the next bidding days, the IPO may witness significant oversubscription, potentially boosting listing expectations.

However, final subscription numbers will be crucial to determine actual listing gains, as momentum can change in the later phases of IPO bidding.